Navigation Links
TGen, Virginia G. Piper Cancer Center studying new breast cancer drug
Date:7/20/2011

SCOTTSDALE, Ariz. July 20, 2011 A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology (ASCO).

The drug under investigation, GDC-0941, manufactured by Genentech Inc., South San Francisco, Calif., targets the PI3K gene, which is abnormal in about 20-30 percent of patients with advanced breast cancer.

In collaboration with the Karmanos Cancer Institute in Detroit, Mich. and the Dana-Farber Cancer Institute in Boston, Mass., Dr. Von Hoff and his team at Virginia G. Piper Cancer Center Clinical Trials initially tested the drug in 97 patients with various advanced cancers. Patients experienced manageable side effects including diarrhea, nausea, taste alteration, rash, fatigue, itchiness, vomiting and decreased appetite.

The study resulted in significant shrinkage of tumors in two patients - one with advanced cervical cancer and one with advanced breast cancer. Another patient with ampullary cancer of the pancreas is currently on the study with stable disease for more than a year.

Dr. Von Hoff is Physician-In-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Chief Scientific Officer at Scottsdale Healthcare and US Oncology. Virginia G. Piper Cancer Center Clinical Trials is a partnership between TGen and Scottsdale Healthcare that treats cancer patients with promising new drugs through clinical trials at the Virginia G. Piper Cancer Center in Scottsdale, Ariz.

"We are very excited about personalizing therapy for breast cancer and gynecologic cancer patients with PI3K inhibitors," said Dr. Von Hoff, who made his presentation in June during ASCO's annual meeting in Chicago. "The next step will be to test samples from breast cancer patients for PI3K mutations and treat those patients accordingly."

Breast cancer remains one of the deadliest cancers among women, with approximately 180,000 new cases each year.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen, Tecan and ASU Biodesign Institute develop sample preparation solution for proteomic research
2. TGen, UA student-researcher extends string of coveted scholarships
3. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
4. Virginia Bioinformatics Institute to model immune responses to gut pathogens
5. Virginia Tech professor discovers new TB pathogen
6. VCU first Virginia institution to join national network of academic research centers
7. Dr. Phillip Chang Introduces New Ways to Decrease Scars and Potential Complications For Breast Augmentations in Loudoun and Fairfax Virginia
8. Virginia Hospital Shared Services Corporation Selects Verified Credentials as its Exclusively Endorsed Provider of Background Screening Services
9. West Virginia EHR Collaborative Adds New Member
10. Internet Security Problems Solved - A New Internet Security Group Defeats CyberCrime in West Virginia
11. Virginia First State to Pass Health Care Freedom Act: 38 States Lining Up Against ObamaCare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 24, 2017 , ... Mediaplanet today announces distribution of its ... obstacles facing infection prevention and offer strategies for the health care community to ... , The print component of “Fighting Infection” is distributed within the Friday, March ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association (RBMA) ... awards, now in their 12th year, are among the most prestigious in radiology marketing ... the awards were retooled to recognize achievements in both large budget (over $5,000) and ...
(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier provider ... caring for those suffering from the full spectrum of disordered eating, announced today that ... professionals from nearly all 50 states and several countries converged on the Green Valley ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the ... product – with nearly 2,000 consumers (and counting) already backing the campaign. ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, ... Claims Litigation seminar in Chicago, Illinois. She will present on: , Filing ... litigated under ERISA involve claims for long-term disability benefits. This session will ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... and is estimated to reach $2,614 million by 2022, Globally, registering a CAGR of ... generate the highest revenue, and is projected to dominate the market during the study ... ... Allied Market Research Logo ...
(Date:3/24/2017)... IRVINE, Calif. , March 24, 2017 ... ,the epigenetics company, and Hamilton Robotics, Inc., ... workstations, announced an ongoing collaboration that teams ... products and RNA and DNA extraction products ... has already created optimized methods for microbiomics ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... report to their offering. ... This report analyzes the worldwide markets for Dental Implants in US$ ... Canada , Japan , Europe ... and Rest of World. Annual estimates and forecasts are ...
Breaking Medicine Technology: